Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579695 · ClinicalTrials.gov registry record
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
A clinical trial, sponsored by Theratechnologies.
- Terminated
- Registry status
- 391
- Enrollment target
NCT01579695 is a clinical trial that was terminated before completion, run by Theratechnologies. The registered enrollment target is 391 participants.
The verdict
NCT01579695 was terminated before completion, sponsored by Theratechnologies.
- TERMINATED
- Registry status
- 391 participants
- Enrollment target
Study Summary
The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
Interventions
- DRUG Tesamorelin for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2013-02 |
| Est. Completion | 2018-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579695
The ClinicalTrials.gov registry entry for NCT01579695 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 391 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theratechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tesamorelin for injection is the first listed.
NCT01579695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01579695 about?
NCT01579695 is a clinical study titled "Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®". The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
What is the current status of trial NCT01579695?
This trial is currently terminated. The enrollment target is 391 participants. The study started on 2013-02. Estimated completion is 2018-08.
What interventions are being tested in trial NCT01579695?
The interventions under investigation include: Tesamorelin for injection (DRUG).
Who is sponsoring clinical trial NCT01579695?
This trial is sponsored by Theratechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.